TransMedics

TransMedics is on a mission to transform the standard of care in solid organ transplantation by replacing decades-old cold storage with its living organ preservation platform, the Organ Care System (OCS™). The company has achieved significant commercial milestones with FDA PMA approvals for its lung, heart, and liver systems and is executing a high-growth strategy through its integrated National OCS™ Program (NOP™). This strategy combines proprietary technology with comprehensive clinical services to drive adoption, increase transplant volumes, and establish a new ecosystem in organ logistics.

The Organ Care System (OCS™) is a portable, normothermic perfusion platform that maintains donor hearts, lungs, and livers in a warm, functioning, and metabolically active state outside the body, enabling extended preservation, objective viability assessment, and long-distance transport.

TransMedics holds a first-mover advantage with the only FDA-approved multi-organ normothermic perfusion platform. Primary competition comes from Paragonix (advanced cold storage) and XVIVO (hypothermic lung perfusion). The company's deep integration with transplant centers via its NOP™ service model creates a significant commercial moat.